Log in

Relevant bibliographies by topics / Prostate cancer survival / Journal articles

To see the other types of publications on this topic, follow the link: Prostate cancer survival.

Journal articles on the topic 'Prostate cancer survival'

Author: Grafiati

Published: 4 June 2021

Last updated: 18 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Prostate cancer survival.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tindall, Donald J. "S1 Molecular Mechanisms of Prostate Cancer Cell Survival following Androgen Ablative Therapy." Japanese Journal of Urology 97, no. 2 (2006): 127. http://dx.doi.org/10.5980/jpnjurol.97.127_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lotan, Yair, Jeffrey A. Cadeddu, J. Jack Lee, Claus G. Roehrborn, and Scott M. Lippman. "Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes." Journal of Clinical Oncology 23, no. 9 (2005): 1911–20. http://dx.doi.org/10.1200/jco.2005.03.137.

Full text

Abstract:

Purpose To assess the estimated effect of finasteride prevention of prostate cancer on overall survival. Methods Data for our decision tree model came from men in the two arms (finasteride or placebo) of the Prostate Cancer Prevention Trial (PCPT) and from clinically localized prostate cancer patients studied for long-term survival outcomes. Our model compared survival outcomes for men treated with finasteride or placebo. Prostate cancer rates were based on the 7-year period prevalence of prostate cancer detected in the PCPT; survival probabilities were abstracted from the long-term outcome st

APA, Harvard, Vancouver, ISO, and other styles

3

Smailytė, Giedrė, Robertas Adomaitis, Karolis Ulinskas, and Birutė Aleknavičienė. "Prostate cancer patient’s survival in Lithuania." Acta medica Lituanica 19, no. 4 (2013): 439–44. http://dx.doi.org/10.6001/actamedica.v19i4.2554.

Full text

Abstract:

Background. The aim of this study was to evaluate changes in the survival of prostate cancer patients during the 12-year period and to analyze differences in survival by period of diagnosis, stage of disease, age and place of residence. Materials and methods. All newly diagnosed cases of prostate cancer (ICD-10, C61) in men were identified in the Lithuanian Cancer Registry for the period 1994–2005. Five-year relative survival estimates were computed with the Hakulinen method using the STATA software. Five-year relative survival estimates were calculated for three different periods of time when

APA, Harvard, Vancouver, ISO, and other styles

4

Feng, Felix Yi-Chung, Shuang Zhao, Seiwon Laura Chang, et al. "Luminal and basal subtyping of prostate cancer." Journal of Clinical Oncology 35, no. 6_suppl (2017): 3. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.3.

Full text

Abstract:

3 Background: There is a clear need to develop a clinically relevant molecular subtyping approach for prostate cancer. We hypothesized that prostate cancer can be subtyped based on luminal versus basal lineage. Methods: We applied the PAM50 classifier, which is used clinically to identify luminal and basal cancers in breast cancer, to subtype a total of 3,782 prostate cancer samples using a high-density microarray platform run in a CLIA-certified laboratory. We examined the associations of these subtypes and clinical outcomes. Results: We demonstrate that PAM50 segregates prostate cancer into

APA, Harvard, Vancouver, ISO, and other styles

5

Bradley, Cathy J., Bassam Dahman, and Mitchell Anscher. "Prostate Cancer Treatment and Survival." Medical Care 52, no. 6 (2014): 482–89. http://dx.doi.org/10.1097/mlr.0000000000000113.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bennett, Alan H. "Prostate Cancer: Making Survival Decisions." JAMA: The Journal of the American Medical Association 273, no. 17 (1995): 1394. http://dx.doi.org/10.1001/jama.1995.03520410090038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Froehner, Michael. "Age and Prostate Cancer Survival." JAMA 303, no. 1 (2010): 33. http://dx.doi.org/10.1001/jama.2009.1933.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Patterson, K. David. "Prostate cancer: Making survival decisions." Social Science & Medicine 41, no. 9 (1995): 1336. http://dx.doi.org/10.1016/0277-9536(95)90067-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kachuri, L., P. De, LF Ellison, and R. Semenciw. "Cancer incidence, mortality and survival trends in Canada, 1970–2007." Chronic Diseases and Injuries in Canada 33, no. 2 (2013): 69–80. http://dx.doi.org/10.24095/hpcdp.33.2.03.

Full text

Abstract:

Introduction Monitoring cancer trends can help evaluate progress in cancer control while reinforcing prevention activities. This analysis examines long-term trends for selected cancers in Canada using data from national databases. Methods Annual changes in trends for age-standardized incidence and mortality rates between 1970 and 2007 were examined by sex for 1) all cancers combined, 2) the four most common cancers (prostate, breast, lung, colorectal) and 3) cancers that demonstrate the most recent notable changes in trend. Five-year relative survival for 1992–2007 was also calculated. Results

APA, Harvard, Vancouver, ISO, and other styles

10

Li, Chunde, Zhuochun Peng, Lambert Skoog, et al. "A gene expression signature to predicit overall, prostate cancer, and non–prostate cancer survival." Journal of Clinical Oncology 31, no. 6_suppl (2013): 51. http://dx.doi.org/10.1200/jco.2013.31.6_suppl.51.

Full text

Abstract:

51 Background: For prostate cancer patients, prostate cancer specific and non-prostate cancer specific survival have the same importance. This study aimed at identifying expression biomarkers that can predict prostate cancer specific, non-prostate cancer specific and overall survival at diagnosis. Methods: Selected ESCGPs (embryonic stem cell gene predictors) and control genes were analyzed by multiplex quantitative PCR using prostate fine-needle aspiration samples taken at diagnosis from a Swedish cohort of 189 prostate cancer patients diagnosed between 1986 and 2000. Of all patients, 97.9% h

APA, Harvard, Vancouver, ISO, and other styles

11

Alavi, Seyed Navid, Chibuzo Eze, and Poornima Pandellapalli. "Racial disparities in cancer survival: A trend analysis based on SEER data (1973-2010)." Journal of Clinical Oncology 37, no. 15_suppl (2019): 1571. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1571.

Full text

Abstract:

1571 Background: African Americans have higher incidence of cancer and lower survival rates compared to other ethnicities. We studied the 5-year relative survival between black and white races for the most common cancers in the United States. Methods: Data was obtained from the SEER database, the largest population-based cancer database including 28% of US population. Data containing 5-year relative survival from the patients who were diagnosed from 1973 to 2010. We included data for cancers of colorectal, lung, prostate, breast and melanoma, the most common cancers in the United States. Resul

APA, Harvard, Vancouver, ISO, and other styles

12

Patrick, AL, JB Nelson, JL Weissfeld, et al. "Prostate Cancer Screening in Men of African Descent: 15-year Results of the Tobago Prostate Cancer Survey." West Indian Medical Journal, Vol 67, Issue 4: 2018 (December 31, 2018): 334–43. http://dx.doi.org/10.7727/wimj.2016.312.

Full text

Abstract:

Objective: To compare all-cause-mortality in screening-detected prostate cancer cases versus non-cases after a median 12.2-year follow-up. Methods: In this prospective, population-based study of 3089 Afro-Caribbean men aged 40–79 years in Tobago, Trinidad and Tobago, West Indies, all men were screened for prostate cancer (serum prostate specific antigen and/or digital rectal exam) one to three times between 1997 and 2007 and followed for mortality to 2012. Among 502 men diagnosed with prostate cancer, 81 younger men underwent radical retropubic prostatectomy. Minimal treatment was available fo

APA, Harvard, Vancouver, ISO, and other styles

13

Warnecke, Brian, Raissa Lakene Djoufack Djoumessi, Juan Garza, Michael Mader, Shreya Chaudhary, and Paromita Datta. "The effect of statins on overall survival and progression-free survival in veterans with prostate cancer: A retrospective single-center experience." Journal of Clinical Oncology 39, no. 6_suppl (2021): 169. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.169.

Full text

Abstract:

169 Background: Prostate cancer is the most common cancer in men in the United States. Death in prostate cancer patients is often related to other medical conditions and not prostate cancer itself. Hence, it is important to optimize other co-morbidities, such as hyperlipidemia, hypertension, and cardiovascular diseases in these patients. However, there are numerous studies portraying the ability of statins to increase progression free survival and overall survival of prostate cancer. This has led to significant interest of statins having anti-cancer properties and ultimately improving long ter

APA, Harvard, Vancouver, ISO, and other styles

14

Deantoni, Chiara Lucrezia, Andrei Fodor, Cesare Cozzarini, et al. "Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases." British Journal of Radiology 93, no. 1108 (2020): 20190353. http://dx.doi.org/10.1259/bjr.20190353.

Full text

Abstract:

Objective: To evaluate toxicity and clinical outcome in synchronous bone only oligometastatic (≤2 lesions) prostate cancer patients, simultaneously irradiated to prostate/prostatic bed, lymph nodes and bone metastases. Methods: From 2/2009 to 6/2015, 39 bone only prostate cancer patients underwent radiotherapy (RT) at “radical” doses to bone metastases (median 2 Gy equivalent dose, EQD2>40Gy, α/β = 1,5), nodes, and prostate/prostatic bed, within the same RT course, in association with androgen deprivation therapy (ADT). Biochemical relapse-free survival, clinical relapse-free survival, free

APA, Harvard, Vancouver, ISO, and other styles

15

Kim, Jae-Heon, Hee-Jo Yang, Chang-Ho Lee, et al. "The Positive Correlations between the Expression of Histopathological Ubiquitin-Conjugating Enzyme 2O Staining and Prostate Cancer Advancement." Pharmaceuticals 14, no. 8 (2021): 778. http://dx.doi.org/10.3390/ph14080778.

Full text

Abstract:

Background: The mTOR signaling pathway is inactivated by AMPK’s tumor-suppressing function. It is recognized that ubiquitin conjugating enzyme 2O (UBE2O), which directly targets AMPK for ubiquitination and degradation, is intensified in human cancers. Methods: This study investigated the clinical data about prostate cancer. Examination was also carried out into tissue microarrays (TMA) of human prostate cancer (n = 382) and adjacent non-neoplastic tissues around prostate cancer (n = 61). The TMA slides were incubated with antibodies against UBE2O, and the cores were scored by the pathologist b

APA, Harvard, Vancouver, ISO, and other styles

16

&NA;. "Diethylstilbestrol: survival advantage in prostate cancer." Inpharma Weekly &NA;, no. 1056 (1996): 16. http://dx.doi.org/10.2165/00128413-199610560-00032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

EVANS, JEFF. "Prostate Cancer Vaccine Increased Overall Survival." Clinical Psychiatry News 33, no. 7 (2005): 61. http://dx.doi.org/10.1016/s0270-6644(05)70550-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Bicalutamide extends survival in prostate cancer." Oncology Times 3, no. 3 (2006): 3. http://dx.doi.org/10.1097/01434893-200603000-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Wilding, George, and Patrick Remington. "Period Analysis of Prostate Cancer Survival." Journal of Clinical Oncology 23, no. 3 (2005): 407–9. http://dx.doi.org/10.1200/jco.2005.09.906.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Lu-Yao, Grace L. "Age and Prostate Cancer Survival—Reply." JAMA 303, no. 1 (2010): 33. http://dx.doi.org/10.1001/jama.2009.1934.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Kawada, Tomoyuki. "Dairy intake and prostate cancer survival." International Journal of Cancer 140, no. 12 (2017): 2830. http://dx.doi.org/10.1002/ijc.30703.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Renner, Wilfried, Uwe Langsenlehner, Sabine Krenn-Pilko, Petra Eder, and Tanja Langsenlehner. "BCL2 genotypes and prostate cancer survival." Strahlentherapie und Onkologie 193, no. 6 (2017): 466–71. http://dx.doi.org/10.1007/s00066-017-1126-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Kirichek, A. A., L. N. Lyubchenko, and V. B. Matveev. "Risk-adapted approach to prostate cancer screening." Cancer Urology 14, no. 2 (2018): 109–21. http://dx.doi.org/10.17650/1726-9776-2018-14-2-109-121.

Full text

Abstract:

Mass prostatic specific antigen (PSA) testing (population-based PSA screening) has remained controversial, nevertheless there are men cohorts likely to benefit from PSA screening. Heritable factors contribute to 60 % risk for developing familial prostate cancer. Despite the fact that its clinical application is challenging due to polygenic inheritance, advances in new generation sequencing technologies permit identifying highly penetrant germline mutations in genes BRCA1, BRCA2, CHEK2, HOXB13 and MMR associated with tremendous increase in risk of developing the prostate cancer. Several germlin

APA, Harvard, Vancouver, ISO, and other styles

24

Lin, Po-Hung, Jui-Ming Liu, Ren-Jun Hsu, et al. "Depression Negatively Impacts Survival of Patients with Metastatic Prostate Cancer." International Journal of Environmental Research and Public Health 15, no. 10 (2018): 2148. http://dx.doi.org/10.3390/ijerph15102148.

Full text

Abstract:

The prevalence of depression in patients with cancer is high, especially for patients with advanced cancer. In this study, we evaluated the prevalence of depression in prostate cancer patients in Taiwan and the association between depression and mortality in prostate cancer. This study included 1101 newly diagnosed patients with prostate cancer. We tracked the medical information of these patients from diagnosis until the end of 2012. Patients were divided into two groups according to presence or absence of depression diagnosis, and were further divided into three stages by initial treatments:

APA, Harvard, Vancouver, ISO, and other styles

25

Li, T., M. Thompson, and D. Tran. "Metastatic-Free Survival And Overall Survival In Prostate Cancer." Value in Health 18, no. 3 (2015): A14. http://dx.doi.org/10.1016/j.jval.2015.03.088.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Hemminki, Kari, Jianguang Ji, Asta Försti, Jan Sundquist, and Per Lenner. "Concordance of Survival in Family Members With Prostate Cancer." Journal of Clinical Oncology 26, no. 10 (2008): 1705–9. http://dx.doi.org/10.1200/jco.2007.13.3355.

Full text

Abstract:

Purpose Several earlier studies have assessed survival in prostate cancer based on familial risk of this disease. As a novel concept, we posit that factors governing survival in prostate cancer are likely to be different from those governing risk of prostate cancer. To prove this, we searched for familial clustering of survival (ie, concordance of survival among family members). Patients and Methods We used the nationwide Swedish Family-Cancer Database to estimate hazard rates (HRs) for cause-specific and overall survival in invasive prostate cancer. HRs show the probability of death in the st

APA, Harvard, Vancouver, ISO, and other styles

27

Doja, M. N., Ishleen Kaur, and Tanvir Ahmad. "Age-specific survival in prostate cancer using machine learning." Data Technologies and Applications 54, no. 2 (2020): 215–34. http://dx.doi.org/10.1108/dta-10-2019-0189.

Full text

Abstract:

PurposeThe incidence of prostate cancer is increasing from the past few decades. Various studies have tried to determine the survival of patients, but metastatic prostate cancer is still not extensively explored. The survival rate of metastatic prostate cancer is very less compared to the earlier stages. The study aims to investigate the survivability of metastatic prostate cancer based on the age group to which a patient belongs, and the difference between the significance of the attributes for different age groups.Design/methodology/approachData of metastatic prostate cancer patients was col

APA, Harvard, Vancouver, ISO, and other styles

28

Duffy, M. J. "New Cancer Markers." Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 26, no. 5 (1989): 379–87. http://dx.doi.org/10.1177/000456328902600501.

Full text

Abstract:

In recent years many new and improved cancer markers have become available. From a clinical point of view, the most useful of the new markers include CA 19–9 for pancreatic adenocarcinoma, CA 125 for epithelial ovarian cancer, CA 15–3 for breast cancer, prostate specific antigen for prostatic adenocarcinoma, placental alkaline phosphatase for testicular seminomas and neuron-specific enolase for small cell carcinoma of lung. None of these new markers are specific for cancer. Furthermore, none are organ specific, except prostate specific antigen for prostatic tissue. The main application of thes

APA, Harvard, Vancouver, ISO, and other styles

29

Yang, David Dewei, Santino Butler, Vinayak Muralidhar, et al. "Prostate-directed radiation therapy and overall survival for men with M1a prostate cancer." Journal of Clinical Oncology 38, no. 6_suppl (2020): 101. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.101.

Full text

Abstract:

101 Background: A recent randomized controlled trial demonstrated that radiation therapy to the prostate improves overall survival for men with newly diagnosed metastatic prostate cancer with a low metastatic burden. Most patients in this trial had bony metastases (stage M1b). The benefit of prostate-directed radiation therapy for men with metastases limited to non-regional lymph nodes (stage M1a) is unknown. We investigated the association between prostate-directed radiation therapy and overall survival for men with M1a prostate cancer. Methods: We identified 2,079 men from the National Cance

APA, Harvard, Vancouver, ISO, and other styles

30

Taylor, C. D., P. Elson, and D. L. Trump. "Importance of continued testicular suppression in hormone-refractory prostate cancer." Journal of Clinical Oncology 11, no. 11 (1993): 2167–72. http://dx.doi.org/10.1200/jco.1993.11.11.2167.

Full text

Abstract:

PURPOSE Patients in whom prostate cancer progresses despite testicular androgen ablation are generally said to have cancers that have become resistant to hormonal maneuvers. If androgen suppression has been pharmacologic, this therapy is often stopped before consideration of other systemic treatments. This exploratory study sought clinical correlates of experimental evidence that there may be substantial acceleration of tumor growth after cessation of androgen suppression. MATERIALS AND METHODS A retrospective multivariate analysis was performed on survival data for 341 patients treated on fou

APA, Harvard, Vancouver, ISO, and other styles

31

Srihari, Sriganesh, Ray Kwong, Khoa Tran, Rebecca Simpson, Paula Tattam, and Elliot Smith. "Metabolic deregulation in prostate cancer." Molecular Omics 14, no. 5 (2018): 320–29. http://dx.doi.org/10.1039/c8mo00170g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Mulia, Julius I. "Vaccines for prostate cancer : a new era?" Universa Medicina 28, no. 3 (2016): i—iii. http://dx.doi.org/10.18051/univmed.2009.v28.i-iii.

Full text

Abstract:

Prostate adenocarcinoma is the most prevalent type of noncutaneous cancer in the Western world, with an estimated 218,890 new cases and 27,050 deaths in the United States in 2007. Currently prostate cancer is detected by measurement of prostate-specific antigen (PSA), a serine protease synthesized by the prostatic epithelium. PSA is an organ-specific and tumor-associated antigen (TAA) but it is not tumor-specific.(1) Partly because of increased cancer screening with PSA, prostatic cancer may now be diagnosed when it is still localized. Localized tumors of the prostate are generally treated wit

APA, Harvard, Vancouver, ISO, and other styles

33

Keating, Matthew, Lisa Giscombe, Andre Desouza, Shiva Kumar Reddy Mukkamalla, and Ritesh Rathore. "Patterns of response to androgen deprivation therapy in younger patients with locally advanced or metastatic prostate cancer." Journal of Clinical Oncology 36, no. 6_suppl (2018): 324. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.324.

Full text

Abstract:

324 Background: Androgen deprivation therapy (ADT) remains a standard of care in the treatment of locally advanced prostate cancer. But thanks to a few key trials (STAMPEDE, CHAARTED, and LATITUDE) reported within the past three years, docetaxel and abiraterone now have roles in extending overall survival in a patient population traditionally treated with ADT alone. These treatments when combined with ADT have been shown to extend overall survival in metastatic hormone-sensitive prostate cancer patients. The role of ADT in relation to other therapies continues to evolve rapidly. We intend to r

APA, Harvard, Vancouver, ISO, and other styles

34

Ikeda, Takashi, Hiroki Ishihara, Junpei Iizuka, et al. "Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer." Japanese Journal of Clinical Oncology 50, no. 8 (2020): 933–39. http://dx.doi.org/10.1093/jjco/hyaa045.

Full text

Abstract:

Abstract Background Cancer cachexia is associated with a poor prognosis. This study aimed to investigate the association between sarcopenia and survival in patients with metastatic hormone-sensitive prostate cancer. Methods We retrospectively evaluated 197 patients diagnosed with metastatic hormone-sensitive prostate cancer in our department and its affiliated institution between January 2008 and December 2015. Sarcopenia was diagnosed according to the sex-specific consensus definition. Castration-resistance prostate cancer-free survival, cancer-specific survival and overall survival from the

APA, Harvard, Vancouver, ISO, and other styles

35

Valicenti, Richard, Jiandong Lu, Miljenko Pilepich, Sucha Asbell, and David Grignon. "Survival Advantage From Higher-Dose Radiation Therapy for Clinically Localized Prostate Cancer Treated on the Radiation Therapy Oncology Group Trials." Journal of Clinical Oncology 18, no. 14 (2000): 2740–46. http://dx.doi.org/10.1200/jco.2000.18.14.2740.

Full text

Abstract:

PURPOSE: We evaluated the effect of external-beam radiation therapy on disease-specific survival (death from causes related to prostate cancer) and overall survival in men with clinically localized prostate cancer. METHODS: From 1975 to 1992, 1,465 men with clinically localized prostate cancer received radiation therapy on four Radiation Therapy Oncology Group phase III randomized trials and were pooled for this analysis. No one received androgen-deprivation therapy with his initial treatment. All original histology had central pathologic review for grading using the Gleason classification sys

APA, Harvard, Vancouver, ISO, and other styles

36

Santos, Nilton José, Caroline Nascimento Barquilha, Isabela Correa Barbosa, et al. "Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer." International Journal of Molecular Sciences 22, no. 16 (2021): 8669. http://dx.doi.org/10.3390/ijms22168669.

Full text

Abstract:

Prostate cancer (PCa) is the leading cause of cancer-associated mortality in men, and new biomarkers are still needed. The expression pattern and protein tissue localization of proteoglycans of the syndecan family (SDC 1–4) and syntenin-1 (SDCBP) were determined in normal and prostatic tumor tissue from two genetically engineered mouse models and human prostate tumors. Studies were validated using SDC 1–4 and SDCBP mRNA levels and patient survival data from The Cancer Genome Atlas and CamCAP databases. RNAseq showed increased expression of Sdc1 in Pb-Cre4/Ptenf/f mouse Pca and upregulation of

APA, Harvard, Vancouver, ISO, and other styles

37

Vahedian Ardakani, Hassan Ali, Mansour Moghimi, Mohammad Shayestehpour, Masoud Doosti, and Fahimeh Salari Shahrbabaki. "Survival Outcome in Men with Prostate Cancer in Yazd Province, Central Iran, from 2001 to 2012." Asian Pacific Journal of Cancer Biology 2, no. 2 (2017): 23–26. http://dx.doi.org/10.31557/apjcb.2017.2.2.23-26.

Full text

Abstract:

Background: Prostate cancer is the second-leading cause of cancer death among men in the world. This cancer has increased significantly during recent years in Iran and is the sixth most common malignancy in Iranian men. Survival rates for prostate cancer in Iran are unknown. The present study aimed to estimate survival of patients suffering from prostate cancer in Yazd, Iran.Methods: In this retrospective cohort study, data were collected from 100 men with prostate cancer registered in Shohadaye Kargar and Shahid Sadoughy hospitals in Yazd during the period 2001-2012. The Kaplan-Meier method w

APA, Harvard, Vancouver, ISO, and other styles

38

Cross, N. A., M. Papageorgiou, and C. L. Eaton. "Bone marrow stromal cells promote growth and survival of prostate cancer cells." Biochemical Society Transactions 35, no. 4 (2007): 698–700. http://dx.doi.org/10.1042/bst0350698.

Full text

Abstract:

Prostate cancers frequently metastasize to the skeleton, and it has been hypothesized that this environment selectively supports the growth of these tumours. Specifically there is strong evidence that interactions between tumour cells and BMSCs (bone marrow stromal cells) play a major role in supporting prostate cancer growth and survival in bone. Here, we examine factors shown to be secreted by BMSCs, such as IGFs (insulin-like growth factors) and IL-6 (interleukin 6), shown to promote prostate cancer cell proliferation and to potentially replace the requirement for androgens. In addition we

APA, Harvard, Vancouver, ISO, and other styles

39

Morrell, Christopher H., Michael W. Kattan, F. Roy MacKintosh, Stephen Van Den Eeden, and Thomas B. Neville. "ESTIMATING PROSTATE CANCER RELATIVE SURVIVAL AND CANCER-SPECIFIC DEATH." Advances and Applications in Statistics 46, no. 3 (2015): 197–223. http://dx.doi.org/10.17654/adassep2015_197_223.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Scafoglio, Claudio, Bruce A. Hirayama, Vladimir Kepe, et al. "Functional expression of sodium-glucose transporters in cancer." Proceedings of the National Academy of Sciences 112, no. 30 (2015): E4111—E4119. http://dx.doi.org/10.1073/pnas.1511698112.

Full text

Abstract:

Glucose is a major metabolic substrate required for cancer cell survival and growth. It is mainly imported into cells by facilitated glucose transporters (GLUTs). Here we demonstrate the importance of another glucose import system, the sodium-dependent glucose transporters (SGLTs), in pancreatic and prostate adenocarcinomas, and investigate their role in cancer cell survival. Three experimental approaches were used: (i) immunohistochemical mapping of SGLT1 and SGLT2 distribution in tumors; (ii) measurement of glucose uptake in fresh isolated tumors using an SGLT-specific radioactive glucose an

APA, Harvard, Vancouver, ISO, and other styles

41

Itkonen, Harri M., Michael Brown, Alfonso Urbanucci, et al. "Lipid degradation promotes prostate cancer cell survival." Oncotarget 8, no. 24 (2017): 38264–75. http://dx.doi.org/10.18632/oncotarget.16123.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Kjellman, Anders, Søren Friis, Fredrik Granath, Ove Gustafsson, Henrik Toft Sørensen, and Olof Akre. "Treatment with finasteride and prostate cancer survival." Scandinavian Journal of Urology 47, no. 4 (2012): 265–71. http://dx.doi.org/10.3109/00365599.2012.737366.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Froehner, Michael. "Prostate Cancer–Specific Survival in Elderly Patients." Journal of Clinical Oncology 29, no. 10 (2011): e281-e281. http://dx.doi.org/10.1200/jco.2010.34.2378.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "Goserelin significantly improves survival in prostate cancer." Inpharma Weekly &NA;, no. 1347 (2002): 12. http://dx.doi.org/10.2165/00128413-200213470-00030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

&NA;. "Adjuvant goserelin improves survival in prostate cancer." Inpharma Weekly &NA;, no. 1099 (1997): 14. http://dx.doi.org/10.2165/00128413-199710990-00025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

&NA;. "Longer survival with bicalutamide in prostate cancer?" Inpharma Weekly &NA;, no. 1111 (1997): 16. http://dx.doi.org/10.2165/00128413-199711110-00034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

&NA;. "Androgen suppression improves survival in prostate cancer." Inpharma Weekly &NA;, no. 1622 (2008): 8. http://dx.doi.org/10.2165/00128413-200816220-00022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Clark, Joseph Y., Patricia K. Lillis, Timothy J. O’Rourke, Christina Jones, Betsy A. Higgins, and Ian M. Thompson. "Interobserver variability in prostate cancer specific survival." Urologic Oncology: Seminars and Original Investigations 4, no. 1 (1998): 13–16. http://dx.doi.org/10.1016/s1078-1439(98)00026-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

BIRK, SUSAN. "Provenge Shows Survival Benefit in Prostate Cancer." Internal Medicine News 42, no. 10 (2009): 21. http://dx.doi.org/10.1016/s1097-8690(09)70358-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

MOON, MARY ANN. "Sipuleucel-T Prolongs Survival in Prostate Cancer." Internal Medicine News 43, no. 13 (2010): 60. http://dx.doi.org/10.1016/s1097-8690(10)70697-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!